Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743233 | 0.88 | CHRM3 (0.40) | CHRM3CHRM2 | |
| SCHEMBL5743611 | 0.86 | CYP2D6 (0.39) | CHRM3CYP2D6L3MBTL1 | |
| SCHEMBL5743658 | 0.84 | CHRM3 (0.40) | CHRM3CHRM2MEN1LMNACYP2D6 | |
| SCHEMBL5745637 | 0.83 | L3MBTL1 (0.34) | PIM1PIM3CHRM3CYP2D6L3MBTL1 | |
| SCHEMBL5746294 | 0.80 | CYP2D6 (0.47) | MEN1LMNACYP2D6KMT2A | |
| SCHEMBL5743640 | 0.79 | CYP2D6 (0.41) | CHRM3CHRM2MEN1LMNACYP2D6 | |
| SCHEMBL5746067 | 0.79 | CHRM3 (0.33) | PIM1PIM3CHRM3CHRM2L3MBTL1 | |
| SCHEMBL30214804 | 0.78 | L3MBTL1 (0.39) | PIM1PIM3CHRM3CHRM2MEN1 | |
| SCHEMBL5743623 | 0.77 | L3MBTL1 (0.33) | PIM1PIM3CHRM3CHRM2CYP2D6 | |
| SCHEMBL5744733 | 0.76 | CHRM3 (0.33) | CHRM3CHRM2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1288198-B1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-6992205-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2006-01-31 | — | — | US | disclosed |
| US-6864372-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2005-03-08 | — | — | US | disclosed |
| US-6794519-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20030176713-A1 | Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base | KANEKA CORPORATION (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030176711-A1 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030162966-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORPORATION (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1288198-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORPORATION (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162966-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | TST, STS, SELENOI | PIM1 516/4885PIM3 759/4885CHRM3 3840/4885 |
| US-20030176711-A1 | Process for the production of sulfonic esters | TST, STS, SELENOI | PIM1 516/4885PIM3 759/4885CHRM3 3840/4885 |
| US-20030176713-A1 | Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base | BRAF, ADH1C, TST | PIM1 493/4885PIM3 769/4885CHRM3 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.